App-Quantinova.ai

Gastric and gastroesophageal adenocarcinoma survival outcomes relative to completion of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A single-center retrospective analysis.

Michael J Allen - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Docetaxel

The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An exploratory analysis of JCOG1013.

Shuichi Hironaka - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable esophagogastric junction adenocarcinoma: A retrospective study.

Toshiharu Hirose - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Docetaxel

Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.

Feng Wang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Docetaxel

Confirmed three-year RFS and OS of the randomized trial of adjuvant S-1 versus S-1 plus docetaxel after curative resection of pStage III gastric cancer (JACCRO GC-07).

Kazuhiro Yoshida - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Ning Li - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

Ulka N. Vaishampayan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Cost-effectiveness analysis of pembrolizumab for BCG-unresponsive carcinoma in situ of the bladder.

Vidit Sharma - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.

Thomas Powles - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Docetaxel

CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer.

Karim Fizazi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

Leonard Joseph Appleman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

Docetaxel

177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).

Michael S Hofman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Geographic variation in systemic therapy in men age 66 years and older with de novo metastatic castration-sensitive prostate cancer: A population-based study in a single payer health-system.

Christopher J.D. Wallis - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.

Daniel E Lage - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Jones T. Nauseef - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza).

Nicholas J. Vogelzang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic,castrate-refractory prostate cancer (mCRPC)—A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.

Robert J. Jones - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

The potential role of frailty in modifying quality-of-life related outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel, abiraterone, enzalutamine, and radium 223.

Seungyeon Kim - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Docetaxel

Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).

Tian Zhang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study.

Daniel J. George - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Docetaxel

Filters

2459 Abstracts